Secukinumab was superior to placebo in exhibiting sustained remission at 52 weeks in patients with relapsed polymyalgia rheumatica, according to findings published in the New England Journal of Medicine.“Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips,” John H. Stone, MD, of the division of rheumatology,
Rob Volansky is a Staff Writer at HEMONC TODAY. He covers a wide range of topics within medicine and healthcare, with a focus on rheumatology, immunology, mental health care, and digital health, among others. His work has been featured in Healio, highlighting his commitment to providing insightful coverage on patient care, public health, and the evolving healthcare system.













